Bayer HealthCare
Bayer Schering Pharma
-
Thursday - November 19, 2009
Positive Results from Chronic Study with Bayer’s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
Endpoints met in EINSTEIN-Extension Trial in the Secondary Prevention of Recurrent Symptomatic VTE
-
Wednesday - October 28, 2009
European Journalists’ Prize 2009 announced
Association of German Medical Journalists (VDMJ) and Bayer HealthCare honor good medical reporting
-
Tuesday - October 27, 2009
Bayer AG News Conference Call and Report for the Third Quarter of 2009
-
Tuesday - October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed
-
Friday - October 23, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
-
Thursday - October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
-
Thursday - October 8, 2009
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy
-
Monday - October 5, 2009
Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):
Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding
Results also confirm significant improvement in blood iron levels
-
Wednesday - September 30, 2009
Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Preliminary results require further analysis and interpretation
-
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany
-
Tuesday - September 22, 2009
Leading-edge medical research and development:
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
Development of the novel anticoagulant rivaroxaban commended / Three research and development teams on shortlist
-
Tuesday - September 22, 2009
Contribution to the fight against tropical diseases
Bayer to supply WHO with a product for the combination therapy of African sleeping sickness
New combination therapy added to the WHO's Essential Drug List
-
Tuesday - September 22, 2009
Results of a Phase II study in Renal Cell Carcinoma (RCC):
Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009
-
Thursday - September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions
-
Thursday - September 10, 2009
European Multiple Sclerosis Congress ECTRIMS:
Recent Research Supports the Importance of Starting Treatment Early in Patients with Multiple Sclerosis (MS)
New data show impact of hidden symptoms in early MS
-
Thursday - September 10, 2009
New data presented at European Multiple Sclerosis Congress ECTRIMS:
Betaferon® may play a role in the protection of brain tissue
-
Thursday - September 3, 2009
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients
Phase III compound represents potential therapy for life-threatening condition
-
Wednesday - September 2, 2009
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.
Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate® and NeoBenz® Micro
-
Sunday - August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute’s launch of GARFIELD – a global patient Registry to evaluate ‘real life’ outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.
-
Wednesday - August 19, 2009
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction
Search
Links
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection